Clinical Trial Update: A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the safety and antitumor activity of IPI-504 in patients with metastatic melanoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• IPI-504 (retaspimycin hydrochloride)

Snippet

Sponsor: Infinity Pharmaceuticals, Inc. | Conditions: Metastatic Melanoma | Phase 2 | Status: TERMINATED